CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT the same day.
Participants can access the live webcast and archived replay on CytomX's Events and Presentations page and are advised to register at least 10 minutes before the call.
Details
News Market Reaction – CTMX
On Mar 4, the day this news came out, CTMX closed 5.41% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Earnings date
- March 16, 2026
- Scheduled full year 2025 results release before U.S. market open
- Conference call time (ET)
- 8:00 a.m. ET
- Earnings conference call start time
- Conference call time (PT)
- 5:00 a.m. PT
- Earnings conference call start time
Historical Context
-
Announced management presentations at two February 2026 investor conferences with webcast access.
-
Outlined 2026 clinical milestones for CX-2051 and CX-801, including Phase 1 expansions.
-
Detailed December 2025 investor conference fireside chats with webcast availability for investors.
-
CEO scheduled for a fireside chat at the Jefferies London Healthcare Conference with webcast.
-
Reported Q3 2025 financials, including $6.0M revenue and $143.6M cash with runway to Q2 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.